Jul 5, 2024 | Biosimilar, Cost Savings, Drug costs, Humira, Idacio, MedBen Rx, News, Rx Costs, Savings
The Food and Drug Administration is considering a change to its biosimilar policy that would greatly speed up their approval process – which, if enacted, would be a big win for MedBen Rx clients who are already reducing their prescription drug spend through...
Jun 10, 2024 | Affordable Care Act, Caroline Fraker, Wegovy, Weight loss, Weight loss drugs, Zepbound
While most health plans do not currently cover obesity medications like Wegovy and Zepbound – and MedBen Rx recommends clients continue not to do so – constant media coverage means the calls to do so will only grow. Therefore, employers are increasingly considering...
May 29, 2024 | Announcements, Caroline Fraker, Doug Freeman, Kurt Harden, MedBen Board of Directors\, MedBen employees
At the recent Annual Meeting for MedBen, Doug Freeman, who for over 36 years served as President and later Chairman of Medical Benefits Mutual Life Insurance Co. (MedBen), retired from the Board of Directors. At the same meeting, Kurt Harden, previously MedBen’s...
May 24, 2024 | Announcements, Compliance, Consolidated Appropriations Act of 2021 (CAA), Regulatory
You might remember that the Consolidated Appropriations Act of 2021 (CAA) requires all health plans to file a pharmacy data report annually to the Centers for Medicare & Medicaid Services (CMS). Each year, the Prescription Drug Data Collection reporting (RxDC)...
May 13, 2024 | Diabetes, Kurt Harden, MedBen University, Mounjaro, Ozempic, Wegovy, Weight loss, Zepbound
At recent MedBen University roundtables, MedBen President & CEO Kurt Harden examined how the growing public awareness of two diabetes drugs with a desirable side effect – significant weight loss – means that these $1,000-per-month medications are not always being...
